干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*

doi:10.3969/j.issn.1672-5069.2019.05.009

摘要/Abstract

摘要： 目的观察干扰素α-2b与聚乙二醇干扰素α-2a（PEG-IFNα-2a）治疗慢性乙型肝炎（CHB）患者的临床疗效。方法将116例CHB患者分成两组,每组58例。给予对照组普通干扰素α-2b治疗,给予观察组PEG-IFNα-2a,疗程均为48 w。检测血清层黏连蛋白（LN）、透明质酸（HA）、Ⅳ型胶原（Ⅳ-C）、Ⅲ型前胶原肽（PⅢP）及血清白介素4（IL-4）、白介素6（IL-6）、白介素10（IL-10）和干扰素γ（IFN-γ）变化。结果在治疗结束时,观察组HBV DNA转阴率、HBeAg转阴率、HBeAg血清转换率和ALT复常率分别为75.9%、29.3%、22.4%和70.7%,显著高于对照组的51.7%、19.0%、10.3%和55.2%（P<0.05）;观察组血清LN为（148.5±46.0） μg/L,显著低于对照组【（162.6±26.7） μg/L,P<0.05】,血清HA为（158.7±67.9）μg/L,显著低于对照组【（201.4±55.1） μg/L,P<0.05】,血清Ⅳ-C为（108.3±33.4） μg/L,显著低于对照组【（119.2±62.4） μg/L,P<0.05】,血清PⅢP为（145.8±47.2） μg/L,显著低于对照组【（155.3±36.7）μg/L,P<0.05】;观察组血清IL-4水平为（1.5±0.6） pg/ml,显著低于对照组【（3.9±1.6） pg/ml,P<0.05】,而IL-6水平为（6.9±1.3） pg/ml,显著高于对照组【（3.6±0.9） pg/ml,P<0.05】,IL-10水平为（22.6±13.4） pg/ml,显著低于对照组【（17.3±11.4） pg/ml,P<0.05】,IFN-γ水平为（37.2±10.2） pg/ml,显著高于对照组【（28.3±10.5） pg/ml,P<0.05】;观察组血小板计数减少发生率为51.7%,显著高于对照组的12.1%（P<0.05）。结论 PEG-IFNα-2a治疗CHB患者临床疗效优于普通干扰素α-2b,能持久有效地抑制HBV复制,改善血清肝纤维化指标,但不良反应较大,应及时处理。

关键词: 慢性乙型肝炎, 干扰素α-2b, 聚乙二醇干扰素α-2a, 治疗

Abstract: Objective To compare the efficacy of interferon alpha -2b and peginterferon alpha -2a（PEG-IFN alpha-2a） in the treatment of patients with chronic hepatitis B（CHB）. Methods 116 patients with CHB were enrolled in our hospital between August 2015 and August 2017,and were divided randomly into two groups,with 58 in each. The patients in control were treated with interferon alpha -2b,and those in the observation group were treated with PEG-IFN alpha-2a. The regimen in both groups lasted for 48 weeks. Serum laminin （LN）,hyaluronic acid （HA）,collagen type Ⅳ （Ⅳ-C） and pro-Ⅲ type collagen peptide （P Ⅲ P） and serum interleukin 4（IL-4）,IL-6,IL-10 and interferon gamma（IFN-gamma） were detected. Results Serum HBV DNA negative conversion,HBeAg negative conversion,serum HBeAg conversion to anti-HBe and ALT normalization rates in the observation group were 75.9%,29.3%,22.4% and 70.7%,all significantly higher than 51.7%,19.0%,10.3% and 55.2%,respectively （P<0.05）;serum LN,HA,Ⅳ-C and PⅢP levels were significantly lower than in thecontrol （P<0.05）;serum IL-4 level was significantly lower than,while serum IL-6,IL-10 and IFN-γ levels significantly higher than in the control （P<0.05）;the incidence of thrombocytop nia was 51.7%,much higher than 12.1% in the control（P<0.05）. Conclusion PEG-IFN alpha-2a might be superior to domestic IFN alpha-2b in the treatment of patients with CHB,which should be the first-line choice for antiviral therapy.

Key words: Hepatitis B, Interferon alpha-2b, Peginterferon alpha-2a, Therapy

涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.

Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.

参考文献

[1] Hundie GB,Raj VS,Gebre MD,et al.Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia. J Med Virol,2016,88(6):1035-1043.
[2] Sugauchi F,Mizokami M,Orito E,et al.Hepatitis B virus infection among residents of a nursing home for the elderly:seroepidemiological study and molecular evolutionary analysis. J Med Virol,2015,62(4):456-462.
[3] 罗丹,陈勇,陈清,等. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者外周血T淋巴细胞亚群和血清细胞因子水平变化. 实用肝脏病杂志,2018,21(2):200-203.
[4] Mandrik O,Knies S,Golubovska O,et al.Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine. Open Med,2015,10(1):25-33.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[6] Ding Y,Lou J,Hong C,et al.Tolerability,pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection. Br J Clin Pharmacol,2017,83(5):1056-1071.
[7] Ting L,Guang X,Yuan X.Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol,2016,22(46):10210-10218.
[8] 余佳平,侯炜. 聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效预测因素分析. 实用肝脏病杂志,2015,18(5):476-481.
[9] 李卫,李丽军,李永华,等. 回顾性分析聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎患者抗病毒方案调整分析. 中华医院感染学杂志,2017,27(14):3192-3195.
[10] Huang Y,Li M H,Hou M,et al.Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int,2017,16(5):470-479.
[11] Büchner A,Plessis NMD,Reynders DT,et al.Nosocomial outbreak of hepatitis B virus infection in a pediatric hematology and oncology unit in South Africa:Epidemiological investigation and measures to prevent further transmission. Pediat Blood Cancer,2015,62(11):1914-1919.
[12] Marcellin P,Sang H A,Ma X,et al.Combination of tenofovir disoproxil fumarate and peginterferon alfa-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology,2016,150(1):134-144.
[13] Hsu C S,Liu W L,Chao Y C,et al.Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. Hepatol Int,2015,9(2):231-242.
[14] Liu Y,Cheng L,Jiang W.P0566:Autophagy of CD4+T cells: A new mechanism of self-regulation in the process of chronic hepatitis B virus infection. J Hepatol,2015,62(4):S527-S527.
[15] Zhu HL,Li X,Li J,et al.Genetic variation of occult hepatitis B virus infection. World J Gastroenterol,2016,22(13):3531-3546.
[16] Stelma F,Van d RMH,Jansen L,et al. HBsAg loss after peginterferon and nucleotide combination treatment in chronic hepatitis B patients:5 years of follow-up. J Viral Hepat,2017,24(12):1107-1113.
[17] Chan LY,Messinger D,Papatheodoridis GV,et al.A genotype-specific baseline score to predict post-treatment response to peginterferon alfa-2a in HBeAg-positive patients with hepatitis B virus genotype B or C infection. alfa-2a in HBeAg-positive patients with hepatitis B virus genotype B or C infection. J Hepatol,2016,64(2):S589-S590.
[18] Lampertico P,Messinger D,Cornberg M,et al.A genotype-specific baseline score to predict response at 48 weeks post-treatment to peginterferon alfa-2a in patients with HBeAg-negative chronic hepatitis B. J Hepatol,2016,64(2):S599-S600.
[19] Gschwantler M,Laferl H,Vogel W,et al.Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy:final results of the austrian peghope study. Wiener Klinische Wochenschrift,2017,53(5):1-8.
[20] Martinot-Peignoux M,Lapalus M,Maylin S,et al.Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients. J Hepatol,2016,23(11):905-911.